4164-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Parts 520, 524, and 558

[Docket No. FDA-2015-N-0002]

New Animal Drugs; Approval of New Animal Drug Applications

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule; technical amendments.

SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect application-related actions for new animal drug applications (NADAs) and abbreviated new animal drug applications (ANADAs) during May and June 2015. FDA is also informing the public of the availability of summaries of the basis of approval and of environmental review documents, where applicable. The animal drug regulations are also being amended to reflect a nonsubstantive change. This technical amendment is being made to improve the accuracy of the regulations.

DATES: This rule is effective [INSERT DATE OF PUBLICATION IN THE FEDERAL REGISTER].

FOR FURTHER INFORMATION CONTACT: George K. Haibel, Center for Veterinary Medicine (HFV-6), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 240-402-5689, george.haibel@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: FDA is amending the animal drug regulations to reflect

approval actions for NADAs and ANADAs during May and June 2015, as listed in table 1. In addition, FDA is informing the public of the availability, where applicable, of documentation of environmental review required under the National Environmental Policy Act (NEPA) and, for actions requiring review of safety or effectiveness data, summaries of the basis of approval (FOI Summaries) under the Freedom of Information Act (FOIA). These public documents may be seen in the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday. Persons with access to the Internet may obtain these documents at the CVM FOIA Electronic Reading Room:

http://www.fda.gov/AboutFDA/CentersOffices/OfficeofFoods/CVM/CVMFOIAElectronicReadingRoom/default.htm. Marketing exclusivity and patent information may be accessed in FDA's publication, Approved Animal Drug Products Online (Green Book) at:

 $\underline{http://www.fda.gov/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/default.htm}.$

Table 1.--Original and Supplemental NADAs and ANADAs Approved During May and June 2015

NADA/		New Animal Drug		21 CFR	FOIA	NEPA
ANADA	Sponsor	Product Name	Action	Sections	Summary	Review
141-417	Bayer HealthCare LLC	CORAXIS (moxidectin) Topical	Original approval for the	524.1450	yes	$CE^{1,2}$
	Animal Health Division	Solution for Dogs	prevention of heartworm disease,			
	P.O. Box 390		and for the treatment and control of			
	Shawnee Mission, KS 66201		intestinal hookworm, roundworm			
			and whipworm infections in dogs			
141-188	Merial Inc.,	MARQUIS	Supplemental approval of a revised	520.1855	yes	CE ^{1,2}
	3239 Satellite Blvd., Bldg. 500,	(ponazuril)	dosage that includes a loading dose			
	Duluth, GA 30096-4640	Oral Paste	on the first day of treatment			
141-262	Zoetis Inc.	CERENIA	Supplemental approval extending	520.1315	yes	CE ^{1,2}
	333 Portage St.	(maropitant citrate)	duration of daily administration			
	Kalamazoo, MI 49007	Tablets	until resolution of acute vomiting			
141-291	Dechra, Ltd.,	VETORYL	Supplemental approval of a 5-	520.2598	no	CE ^{1,2}
	Snaygill Industrial Estate, Keighley Rd.,	(trilostane)	milligram capsule size			
	Skipton, North Yorkshire,	Capsules				
	BD23 2RW, United Kingdom					
141-278	Intervet, Inc.,	ZILMAX (zilpaterol hydrochloride)	Supplemental approval to provide	558.665	yes	CE ^{1,3}
	2 Giralda Farms,	plus	for component feeding of			
	Madison, NJ 07940	RUMENSIN (monensin)	combination drug Type C			
		Type A medicated articles	medicated feeds to cattle fed in			
			confinement for slaughter			

141-282	Intervet, Inc., 2 Giralda Farms, Madison, NJ 07940	ZILMAX (zilpaterol hydrochloride) plus RUMENSIN (monensin) plus MGA (melengestrol acetate) Type A medicated articles	Supplemental approval to provide for component feeding of combination drug Type C medicated feeds to heifers fed in confinement for slaughter	558.665	yes	CE ^{1,3}
141-284	Intervet, Inc., 2 Giralda Farms, Madison, NJ 07940	ZILMAX (zilpaterol hydrochloride) plus MGA (melengestrol acetate) Type A medicated articles	Supplemental approval to provide for component feeding of combination drug Type C medicated feeds to heifers fed in confinement for slaughter	558.665	yes	CE ^{1,3}
200-497	Norbrook Laboratories, Ltd., Station Works, Newry BT35 6JP, Northern Ireland	LOXICOM (meloxicam) 1.5 mg/mL Oral Suspension	Original approval as a generic copy of NADA 141-213	520.1367	yes	CE ^{1,3}
200-580	Huvepharma AD, 5th Floor, 3A Nikolay Haytov Str., 1113 Sophia, Bulgaria	TYLOVET (tylosin phosphate) plus SACOX (salinomycin sodium) Type C medicated feeds	Original approval as a generic copy of NADA 141-198	558.550 ⁴	yes	CE ^{1,3}

¹The Agency has determined that this action is categorically excluded (CE) from the requirement to submit an environmental assessment or an environmental impact statement because it is of a type that does not have a significant effect on the human environment.

²CE granted under 21 CFR 25.33(d)(1).

³CE granted under 21 CFR 25.33(a)(1).

⁴The regulation does not require amendment.

5

Also, the animal drug regulations are being amended to reflect approved labeling for hand feeding bambermycins medicated cattle feed. This technical amendment is being made to improve the accuracy of the regulations.

This rule does not meet the definition of "rule" in 5 U.S.C. 804(3)(A) because it is a rule of "particular applicability." Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.

List of Subjects

21 CFR Parts 520 and 524

Animal drugs.

21 CFR Part 558

Animal drugs, Animal feeds.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 520, 524, and 558 are amended as follows:

PART 520--ORAL DOSAGE FORM NEW ANIMAL DRUGS

1. The authority citation for 21 CFR part 520 continues to read as follows:

Authority: 21 U.S.C. 360b.

2. In § 520.1315, revise paragraph (c)(1) to read as follows:

§ 520.1315 Maropitant.

* * * * *

(c) * * *

(1) <u>Indications for use and amount</u>. (i) For prevention of acute vomiting in dogs 2 to 7 months of age, administer a minimum dose of 2.0 mg per kilogram (/kg) body weight once daily

for up to 5 consecutive days.

- (ii) For prevention of acute vomiting in dogs 7 months of age and older, administer a minimum dose of 2.0 mg/kg body weight once daily until resolution of acute vomiting.
- (iii) For prevention of vomiting due to motion sickness in dogs 4 months of age and older, administer a minimum of 8.0 mg/kg body weight once daily for up to 2 consecutive days.

* * * * *

§ 520.1367 [Amended]

- 3. In § 520.1367, in paragraph (b)(2), remove "No. 013744" and in its place add "Nos. 013744 and 055529".
 - 4. In § 520.1855, revise paragraph (c)(1) to read as follows:

§ 520.1855 Ponazuril.

* * * * *

- (c) * * *
- (1) Amount. Administer orally 15 mg per kilogram (kg) (6.81 mg per pound (lb)) body weight as the first dose, followed by 5 mg/kg (2.27 mg/lb) body weight once daily for a period of 27 additional days.

* * * * *

§ 520.2598 [Amended]

5. In § 520.2598, in paragraph (a), remove "10, 30, or 60 milligrams" and in its place add "5, 10, 30, 60, or 120 milligrams".

PART 524--OPHTHALMIC AND TOPICAL DOSAGE FORM NEW ANIMAL DRUGS

6. The authority citation for 21 CFR part 524 continues to read as follows:

Authority: 21 U.S.C. 360b.

7. In § 524.1450, and revise paragraphs (a), (b), and (d), and remove paragraph (e). The revisions read as follows:

§ 524.1450 Moxidectin.

- (a) Specifications. Each milliliter of solution contains:
- (1) 5 milligrams (mg) moxidectin (0.5 percent solution).
- (2) 25 mg moxidectin (2.5 percent solution).
- (b) Sponsors. See sponsor numbers in § 510.600 of this chapter:
- (1) No. 000010 for use of product described in paragraph (a)(1) of this section as in paragraph (d)(1) of this section;
- (2) No. 000859 for use of product described in paragraph (a)(2) of this section as in paragraph (d)(2) of this section.

* * * * *

- (d) <u>Conditions of use</u>--(1) <u>Cattle</u>--(i) <u>Amount</u>. Administer topically 0.5 mg per kilogram (kg) of body weight.
- (ii) <u>Indications for use</u>. Beef and dairy cattle: For treatment and control of internal and external parasites: gastrointestinal roundworms (<u>Ostertagia ostertagi</u> (adult and L4, including inhibited larvae), <u>Haemonchus placei</u> (adult and L4), <u>Trichostrongylus axei</u> (adult), <u>Ostertagia ostertagi</u> (adult), <u>Trichostrongylus axei</u> (adult and L4), <u>Trichostrongylus axei</u> (adult), <u>Trichostrongylus axei</u> (

<u>bovis</u>); and horn flies (<u>Haematobia irritans</u>). To control infections and to protect from reinfection with <u>H. placei</u> for 14 days after treatment, <u>O. radiatum</u> and <u>O. ostertagi</u> for 28 days after treatment, and D. viviparus for 42 days after treatment.

- (iii) <u>Limitations</u>. A withdrawal period has not been established for this product on preruminating calves. Do not use on calves to be processed for veal. See § 500.25 of this chapter.
- (2) <u>Dogs</u>--(i) <u>Amount</u>. Administer topically a minimum of 1.1 mg per pound (lb) (2.5 mg/kg) of body weight, once monthly using the appropriate preloaded applicator tube.
- (ii) <u>Indications for use</u>. For the prevention of heartworm disease caused by <u>Dirofilaria</u> immitis, as well as the treatment and control of intestinal hookworm (<u>Ancylostoma caninum</u> (adult, immature adult, and <u>L4 larvae</u>) and <u>Uncinaria stenocephala</u> (adult, immature adult, and <u>L4 larvae</u>), roundworm (<u>Toxocara canis</u> (adult and <u>L4 larvae</u>) and <u>Toxascaris leonina</u> (adult)), and whipworm (<u>Trichuris vulpis</u> (adult)) infections in dogs and puppies that are at least 7 weeks of age and that weigh at least 3 lbs.
- (iii) <u>Limitations</u>. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

PART 558--NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS

8. The authority citation for 21 CFR part 558 continues to read as follows:

Authority: 21 U.S.C. 360b, 371.

§ 558.95 [Amended]

9. In § 558.95, in the table in paragraph (d)(4)(ii), in the "Bambermycins in grams/ton" column, remove "2 to 40" and in its place add "2 to 80"; and in the "Limitations" column, remove the first sentence and in its place add "Feed continuously on a hand-fed basis at a rate of

10 to 40 milligrams per head per day in 1 to 10 pounds of supplemental Type C medicated feed.".

10. In § 558.665, revise paragraphs (d)(2) and (e) to read as follows: § 558.665 Zilpaterol.

* * * * *

- (d) * * *
- (2) Labeling of Type A medicated articles and Type B medicated feeds used to manufacture complete Type C medicated feeds shall bear the caution statement in paragraph (d)(3) of this section.

* * * * *

(e) Conditions of use in cattle. It is administered in feed as follows:

Zilpaterol				
hydrochloride	Combination			
in grams/ton	in grams/ton	Indications for use	Limitations	Sponsor
(1) 6.8		Cattle fed in confinement for slaughter: For increased rate of weight gain, improved feed efficiency, and increased carcass leanness in cattle fed in confinement for slaughter during the last 20 to 40 days on feed.	Feed continuously as the sole ration during the last 20 to 40 days on feed to provide 60 to 90 mg zilpaterol hydrochloride per head per day. Withdrawal period: 3 days. See paragraph (d) of this section.	000061
(2) 6.8	Monensin 10 to 40	Cattle fed in confinement for slaughter: For increased rate of weight gain, improved feed efficiency, and increased carcass leanness in cattle fed in confinement for slaughter	Feed continuously as the sole ration during the last 20 to 40 days on feed to provide 60 to 90 mg zilpaterol hydrochloride per head per day and 0.14 to 0.42 mg monensin	000061 000986

		during the last 20 to 40 days on feed; for prevention and control of coccidiosis due to <u>Eimeria</u> bovis and <u>E. zuernii</u> .	per pound of body weight per day depending on the severity of the coccidiosis challenge, up to 480 mg/head/day monensin.	
			Withdrawal period: 3 days. See paragraph (d) of this section. See paragraph § 558.355(d) of this chapter. Monensin as provided by No. 000986 in § 510.600(c) of this chapter.	
(3) 6.8	Melengestrol acetate to provide 0.25 to 0.5 mg/head/d ay	Heifers fed in confinement for slaughter: For increased rate of weight gain, improved feed efficiency, and increased carcass leanness in cattle fed in confinement for slaughter during the last 20 to 40 days on feed; and for suppression of estrus (heat).	Feed continuously as the sole ration during the last 20 to 40 days on feed to provide 60 to 90 mg zilpaterol hydrochloride per head per day. Withdrawal period: 3 days. See paragraph (d) of this section. Melengestrol acetate as provided by Nos. 000986 or 054771 in § 510.600(c) of this chapter.	000061 000986
(4) 6.8	Monensin 10 to 40 plus melengestrol acetate to provide 0.25 to 0.5 mg/head/d ay	Heifers fed in confinement for slaughter: For increased rate of weight gain, improved feed efficiency, and increased carcass leanness in cattle fed in confinement for slaughter during the last 20 to 40 days on feed; for prevention and control of coccidiosis due to Eimeria	Feed continuously as the sole ration during the last 20 to 40 days on feed to provide 60 to 90 mg zilpaterol hydrochloride per head per day and 0.14 to 0.42 mg monensin per pound of body weight per day depending on the severity of the coccidiosis challenge, up	000061 000986

		bovis and E. zuernii; and for	to 480 mg/head/day monensin.	
		suppression of estrus (heat).	Withdrawal period: 3 days.	
			See paragraph (d) of this	
			section. See paragraphs	
			§§ 558.342(d) and 558.355(d)	
			of this chapter.	
			Monensin as provided by	
			No. 000986; melengestrol	
			acetate as provided by	
			Nos. 000986 or 054771 in	
			§ 510.600(c) of this chapter.	
(5) 6.8	Monensin	For increased rate of weight	Feed continuously as the sole	000061
	10 to 40,	gain, improved feed efficiency,	ration during the last 20 to	016592
	plus	and increased carcass leanness	40 days on feed to provide 60	
	tylosin	in cattle fed in confinement for	to 90 mg zilpaterol	
	8 to 10	slaughter during the last 20 to	hydrochloride per head per day	
		40 days on feed; for prevention	and 0.14 to 0.42 mg monensin	
		and control of coccidiosis due	per pound of body weight per	
		to Eimeria bovis and E. zuernii;	day depending on the severity	
		and for reduction of incidence	of the coccidiosis challenge, up	
		of liver abscesses caused by	to 480 mg/head/day monensin.	
		Fusobacterium necrophorum	Withdrawal period: 3 days.	
		and Arcanobacterium	See paragraph (d) of this	
		(Actinomyces) pyogenes.	section. See paragraphs	
			§§ 558.355(d) and 558.625(c)	
			of this chapter.	
			Monensin as provided by	
			No. 000986; tylosin as	
			provided by Nos. 000986 or	
			016592 in § 510.600(c) of this	
			chapter.	
(6) 6.8	Monensin	Heifers fed in confinement for	Feed continuously as the sole	000061

	10 to 40,	slaughter: For increased rate of	ration during the last 20 to	000986
	plus	weight gain, improved feed	40 days on feed to provide 60	016592
	tylosin	efficiency, and increased	to 90 mg zilpaterol	
	8 to 10, plus	carcass leanness in cattle fed in	hydrochloride per head per day	
	melengestrol	confinement for slaughter	and 0.14 to 0.42 mg monensin	
	acetate to	during the last 20 to 40 days on	per pound of body weight per	
	provide 0.25	feed; for prevention and control	day depending on the severity	
	to	of coccidiosis due to Eimeria	of the coccidiosis challenge, up	
	0.5 mg/head/d	bovis and E. zuernii; for	to 480 mg/head/day monensin.	
	ay	reduction of incidence of liver	Withdrawal period: 3 days.	
		abscesses caused by	See paragraph (d) of this	
		Fusobacterium necrophorum	section. See paragraphs	
		and Arcanobacterium	§§ 558.342(d), 558.355(d), and	
		(Actinomyces) pyogenes; and	558.625(c) of this chapter.	
		for suppression of estrus (heat).	Monensin as provided by	
			No. 000986; tylosin as	
			provided by Nos. 000986 or	
			016592; and melengestrol	
			acetate as provided by	
			Nos. 000986 or 054771 in	
			§ 510.600(c) of this chapter.	
(7) 6.8 to 24		Cattle fed in confinement for	Feed continuously during the	000061
		slaughter: For increased rate of	last 20 to 40 days on feed to	
		weight gain, improved feed	provide 60 mg zilpaterol	
		efficiency, and increased	hydrochloride per head per day.	
		carcass leanness in cattle fed in	Withdrawal period: 3 days.	
		confinement for slaughter	See paragraph (d) of this	
		during the last 20 to 40 days on	section.	
		feed.		

(8) 6.8 to 24	Monensin	Cattle fed in confinement for	Feed continuously during the	000061
	10 to 40	slaughter: For increased rate of	last 20 to 40 days on feed to	
		weight gain, improved feed	provide 60 mg zilpaterol	
		efficiency, and increased	hydrochloride per head per day	
		carcass leanness in cattle fed in	and 0.14 to 0.42 mg monensin	
		confinement for slaughter	per pound of body weight per	
		during the last 20 to 40 days on	day depending on the severity	
		feed; and for prevention and	of the coccidiosis challenge, up	
		control of coccidiosis due to	to 480 mg/head/day monensin.	
		Eimeria bovis and E. zuernii.	Withdrawal period: 3 days. See	
			paragraph (d) of this section.	
			See paragraph § 558.355(d) of	
			this chapter.	
			Monensin as provided by	
			No. 000986 in § 510.600(c) of	
			this chapter.	
(9) 6.8 to 24	Melengestrol	Heifers fed in confinement for	Feed continuously during the	000061
	acetate to	slaughter: For increased rate of	last 20 to 40 days on feed to	
	provide 0.25	weight gain, improved feed	provide 60 mg zilpaterol	
	to	efficiency, and increased	hydrochloride per head per day.	
	0.5 mg/head/d	carcass leanness in cattle fed in	Withdrawal period: 3 days. See	
	ay	confinement for slaughter	paragraph (d) of this section.	
		during the last 20 to 40 days on	See paragraph § 558.342(d) of	
		feed; and for suppression of	this part.	
		estrus (heat).	Melengestrol acetate as	
			provided by No. 054771 in	
			§ 510.600(c) of this chapter.	
(10) 6.8 to 24	Monensin	Heifers fed in confinement for	Feed continuously during the	000061
	10 to 40,	slaughter: For increased rate of	last 20 to 40 days on feed to	
	plus	weight gain, improved feed	provide 60 mg zilpaterol	
	melengestrol	efficiency, and increased	hydrochloride per head per day	
	acetate to	carcass leanness in cattle fed in	and 0.14 to 0.42 mg monensin	

	provide 0.25	confinement for slaughter	per pound of body weight per	
	to	during the last 20 to 40 days on	day depending on the severity	
	0.5 mg/head/d	feed; for prevention and control	of the coccidiosis challenge, up	
	ay	of coccidiosis due to Eimeria	to 480 mg/head/day monensin.	
		bovis and E. zuernii; and for	Withdrawal period: 3 days. See	
		suppression of estrus (heat).	paragraph (d) of this section.	
			See paragraphs §§ 558.342(d)	
			and 558.355(d) of this chapter.	
			Monensin as provided by	
			No. 000986; melengestrol	
			acetate as provided by	
			No. 054771 in § 510.600(c) of	
			this chapter.	
(11) 6.8 to 24	Monensin	Cattle fed in confinement for	Feed continuously during the	000061
	10 to 40,	slaughter: For increased rate of	last 20 to 40 days on feed to	
	plus	weight gain, improved feed	provide 60 mg zilpaterol	
	tylosin	efficiency, and increased	hydrochloride per head per day	
	8 to 10	carcass leanness in cattle fed in	and 0.14 to 0.42 mg monensin	
		confinement for slaughter	per pound of body weight per	
		during the last 20 to 40 days on	day depending on the severity	
		feed; for prevention and control	of the coccidiosis challenge, up	
		of coccidiosis due to Eimeria	to 480 mg/head/day monensin.	
		bovis and E. zuernii; and for	Withdrawal period: 3 days.	
		reduction of incidence of liver	See paragraph (d) of this	
		abscesses caused by	section. See paragraphs	
		Fusobacterium necrophorum	§§ 558.355(d) and 558.625(c)	
		and Arcanobacterium	of this chapter.	
		(Actinomyces) pyogenes.	Monensin and tylosin as	
			provided by No. 000986 in	
			§ 510.600(c) of this chapter.	

(12) 6.8 to 24	Monensin	Heifers fed in confinement for	Feed continuously during the	000061
	10 to 40,	slaughter: For increased rate of	last 20 to 40 days on feed to	
	plus	weight gain, improved feed	provide 60 mg zilpaterol	
	tylosin	efficiency, and increased	hydrochloride per head per day	
	8 to 10,	carcass leanness in cattle fed in	and 0.14 to 0.42 mg monensin	
	plus	confinement for slaughter	per pound of body weight per	
	melengestrol	during the last 20 to 40 days on	day depending on the severity	
	acetate to	feed; for prevention and control	of the coccidiosis challenge, up	
	provide 0.25	of coccidiosis due to Eimeria	to 480 mg/head/day monensin.	
	to	bovis and E. zuernii; for	Withdrawal period: 3 days.	
	0.5 mg/head/d	reduction of incidence of liver	See paragraph (d) of this	
	ay	abscesses caused by	section. See paragraphs	
		Fusobacterium necrophorum	§§ 558.342(d), 558.355(d), and	
		and Arcanobacterium	558.625(c) of this chapter.	
		(Actinomyces) pyogenes; and	Monensin and tylosin as	
		for suppression of estrus (heat).	provided by No. 000986;	
			melengestrol acetate as	
			provided by No. 054771 in	
			§ 510.600(c) of this chapter.	
			-	

Dated: August 31, 2015.

Bernadette Dunham,

Director,

Center for Veterinary Medicine.

[FR Doc. 2015-21905 Filed: 9/3/2015 08:45 am; Publication Date: 9/4/2015]